Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the utility of examining biological markers to predict chemoresponse and survival. The subjects consisted of 39 unresectable gastric cancer patients treated with a combination of 5-fluorouracil and cis-platinum. The expression of
p53
, bcl-2, thymidylate synthase (TS), glutathione S-transferase pi (GST-pi), and
vascular endothelial growth factor
(
VEGF
) in the formalin-fixed biopsy samples of primary tumors before chemotherapy was examined immunohistochemically. The positive rate for
VEGF
, bcl-2, TS,
p53
, and GST-pi was 51, 10, 46, 38, and 69%, respectively.
VEGF
-positive cases showed a higher response rate than did negative cases (11 of 20 versus 2 of 19 cases; P = 0.0057). The cases that were negative for
p53
, TS, bcl-2, and GST-pi were more likely to respond to chemotherapy than the cases that were positive for these markers. The 10 cases having 4 or 5 favorable phenotypes (
VEGF
positive,
p53
negative, bcl-2 negative, TS negative, and GST-pi negative) survived longer than the remaining 29 cases (P = 0.0069). Multivariate analysis revealed that the number of favorable phenotypes (> or = 4 versus < or = 3) had a greater impact on survival than performance status (0 versus 1 or 2), age (> 60 years versus < or = 60 years), macroscopic type (scirrhous versus nonscirrhous), histological type (intestinal versus diffuse), or tumor extent (locally advanced versus metastatic). Immunohistochemical examination of biological markers in biopsy samples may be useful in predicting the clinical outcome of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
...
PMID:Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. 962 64
As a result of deprivation of oxygen (hypoxia) and nutrients, the growth and viability of cells is reduced. Hypoxia-inducible factor (HIF)-1alpha helps to restore oxygen homeostasis by inducing glycolysis, erythropoiesis and angiogenesis. Here we show that hypoxia and hypoglycaemia reduce proliferation and increase apoptosis in wild-type (HIF-1alpha+/+) embryonic stem (ES) cells, but not in ES cells with inactivated HIF-1alpha genes (HIF-1alpha-/-); however, a deficiency of HIF-1alpha does not affect apoptosis induced by cytokines. We find that hypoxia/hypoglycaemia-regulated genes involved in controlling the cell cycle are either HIF-1alpha-dependent (those encoding the proteins
p53
, p21, Bcl-2) or HIF-1alpha-independent (p27, GADD153), suggesting that there are at least two different adaptive responses to being deprived of oxygen and nutrients. Loss of HIF-1alpha reduces hypoxia-induced expression of
vascular endothelial growth factor
, prevents formation of large vessels in ES-derived tumours, and impairs vascular function, resulting in hypoxic microenvironments within the tumour mass. However, growth of HIF-1alpha tumours was not retarded but was accelerated, owing to decreased hypoxia-induced apoptosis and increased stress-induced proliferation. As hypoxic stress contributes to many (patho)biological disorders, this new role for HIF-1alpha in hypoxic control of cell growth and death may be of general pathophysiological importance.
...
PMID:Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. 969 72
We examined the significance of expression of
p53
and
vascular endothelial growth factor
(
VEGF
) on the liver metastasis in 155 patients with colorectal cancer. The expression of
p53
,
VEGF
, and microvessel density (MVD) were immunohistochemically studied. There were significant differences between patients positive for
p53
and patients negative for
p53
, between patients positive for
VEGF
and patients negative for
VEGF
, with respect to the occurrence of liver metastases. The frequency of patients positive for both
p53
and
VEGF
in the liver metastases group was significantly higher than that in the control group. The frequency of patients positive for both
p53
and v, both
VEGF
and v in the liver metastases group, was significantly higher than in the control group. MVD in patients positive for
VEGF
was significantly higher than that negative for
VEGF
. Thus,
p53
and
VEGF
expression affects the formation of liver metastases from colorectal cancer by the activation of neovascularization followed by feasibility of the extravasation of tumor cells in the tumor tissue.
...
PMID:[Significance of p53 and VEGF expression in liver metastasis from colorectal cancer]. 970 27
The aim of this study was to investigate the expression of
p53
and bcl2 proteins in a series of 107 non-small cell lung cancers (NSCLC), and to relate such protein expression to neovascularisation and the expression of
vascular endothelial growth factor
(
VEGF
). Moreover, we analysed the prognostic impact of these biological parameters on overall survival, both in univariate and multivariate analyses. An inverse association was found between bcl2 expression and microvessel count (MVC; P = 0.0004) and bcl2 and
VEGF
(P = 0.007). In contrast, a significant association was found between
p53
expression and MVC (P = 0.03) and
p53
and
VEGF
expression (P = 0.04). In univariate analysis, nodal status (P < 0.000001), MVC (P < 0.000001), bcl2 (P = 0.002),
p53
(P = 0.03) and
VEGF
expression (P < 0.000001) significantly affected overall survival, but in multivariate analysis only MVC and
VEGF
expression retained their prognostic influence. Our results suggest that bcl2 and
p53
possibly control the development of tumour angiogenesis in NSCLC, with putative mediation by
VEGF
. Moreover, the important influence of angiogenesis in the progression of NSCLC is further highlighted.
...
PMID:Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. 971 80
Hypoxia is present in several areas of malignant tumours and is thought to result from an inadequate rate of tumour angiogenesis, vascular collapse, or both. The presence and extent of these hypoxic tumour microenvironments have recently been shown to influence tumour progression by regulating both tumour cell survival and the expression of key angiogenic molecules. Recent studies have suggested that mutations in the tumour suppressor gene,
p53
, may play an important role in regulating the adaptive response of tumour cells to hypoxia by enhancing their survival and release of proangiogenic factors such as
vascular endothelial growth factor
. It has even been suggested that hypoxia may select for the survival of the more malignant clones harbouring such genetic defects as mutations in
p53
. Recently, the transcription factor, NFkB, has also been implicated as a novel mediator of the effects of hypoxia and reoxygenation in tumour cells. This article reviews some of the molecular mechanisms subserving the responses of tumour cells to hypoxic stress, particularly the role and relation of NFkB and
p53
in regulating this phenomenon.
...
PMID:Response of tumour cells to hypoxia: role of p53 and NFkB. 971 87
Gene therapy with the tumor suppressor gene
p53
induces cancer cell apoptosis in vitro and in vivo and inhibits tumor growth in nude mice. We hypothesized that, in addition to cancer cell apoptosis, a replication-deficient adenovirus vector which carries the cDNA for human wild-type
p53
(AdCMV.
p53
) may also modulate endothelial cell function and inhibit angiogenesis. Human umbilical vein endothelial cells (HUVEC) were infected at different multiplicities of infection (MOI) with either AdCMV.
p53
, the control vector AdCMV.null or were not infected. Western blot analysis showed
p53
overexpression up to 7 days after infection with AdCMV.
p53
. HUVEC proliferation was either not affected (20 and 50 MOI) or inhibited to comparable levels (100 MOI; P < 0.05) in AdCMV.
p53
- and AdCMV.null-infected versus uninfected cells. HUVEC differentiation into capillary-like structures on reconstituted basement membrane proteins (Matrigel) was assessed 48 h after infection (100 MOI). After 18 h on Matrigel the capillary-like network formed by AdCMV.
p53
-infected HUVEC was less extensive than that formed by both AdCMV.null-infected and uninfected control cells (P < 0.05 versus either control). In contrast, conditioned medium from AdCMV.
p53
-infected HUVEC did not modulate endothelial cell differentiation on Matrigel. The effect of AdCMV.
p53
on angiogenesis in vivo was assessed by injecting this vector subcutaneously in mice; 3 days later Matrigel containing basic fibroblast growth factor (bFGF) was injected at the same site. In other experiments AdCMV.
p53
was injected simultaneously with an Ad vector coding for
vascular endothelial growth factor
(AdCMV.VEGF165) into the rat perirenal fat tissue. AdCMV.
p53
significantly inhibited neovascularization induced by bFGF within the Matrigel plugs (P < 0.05) or by AdCMV.VEGF165 in the fat tissue (P < 0.05). Thus, the anti-angiogenic effect of Ad-mediated wild-type
p53
overexpression may contribute to the ability of this viral vector to inhibit tumor growth.
...
PMID:Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. 974 54
Anaplastic thyroid carcinomas very often harbor the mutations in the tumor suppressor gene
p53
. We have previously shown that wild-type (wt)
p53
gene introduction led to cell growth arrest, but not apoptosis, in
p53
-null anaplastic thyroid carcinoma cells. The present studies were designed to evaluate other therapeutic effects of wt-
p53
gene introduction on
p53
-null thyroid carcinoma cells, as chemo- and radiosensitization and inhibition of angiogenesis have also been described recently as additional therapeutic advantages of wt-
p53
gene introduction in tumor cells with
p53
mutations. A
p53
-null anaplastic thyroid carcinoma cell line, FRO, and a FRO subline stably expressing a temperature-sensitive (ts) mutant of
p53
(p53Val138), tsFRO, were used. ts-
p53
functions as mutant and wt at nonpermissive (37 C) and permissive (32 C) temperatures, respectively. tsFRO showed a prolonged cell doubling time compared to parental FRO when cultured at 32 C, but the cell growth rate was similar between FRO and tsFRO at 37 C. The cytotoxic and clonogenic assays demonstrated that although the sensitivity to three different anticancer agents (cisplatin, 5-fluorocytosine, and doxorubicin) was unaltered, radiosensitivity was enhanced in tsFRO compared to FRO at 32 C. Unexpectedly, in studies on angiogenesis, expression levels of
vascular endothelial growth factor
(an angiogenic factor) messenger ribonucleic acid were similar between FRO and tsFRO, and thrombospondin-1 (an antiangiogenic factor) messenger ribonucleic acid and protein levels were about 2.5-fold lower in tsFRO than FRO at 32 C, although any difference could not be detected in their ability to inhibit in vitro angiogenesis with the culture medium conditioned by tsFRO and FRO at 32 C. These results suggest that
p53
-defective thyroid carcinomas may benefit from the combination of
p53
gene therapy and radiotherapy. However, further study will be necessary to clarify the pathological significance of thrombospondin-1 in angiogenesis and thyroid tumor growth.
...
PMID:Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. 976 82
Recently, it has been reported that
p53 tumor suppressor
gene plays an important role in controlling tumor angiogenesis by regulating expression of
vascular endothelial growth factor
(
VEGF
), which is a well-characterized angiogenic inducer. In this study, we investigated these antigens' expression together with microvessel density, and investigated their clinical importance. One hundred twenty specimens resected from patients with gastric carcinoma were investigated using immunohistochemical methods.
p53
and
VEGF
expression was observed in 42 and 35% tumors, respectively.
p53
and
VEGF
staining status was coincided in 72% tumors, and a significant correlation was found between
p53
and
VEGF
status. The microvessel density, determined by immunostaining for factor VIII-related antigen, was significantly higher in
p53
-positive or
VEGF
-positive tumors. According to prognosis, patients with
p53
-positive tumors had significantly worse survival than those with
p53
-negative tumors. There was also a significant worse survival in the patients with
VEGF
-positive tumors than those with
VEGF
-negative tumors. Moreover, the 5-year survival rate was lowest in the patients with
p53
-positive and
VEGF
-positive tumors, while it was highest in the patients with
p53
-negative and
VEGF
-negative tumors. In conclusion, both
p53
and
VEGF
significantly correlated with tumor vascularity and prognosis in patients with gastric carcinoma.
...
PMID:Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. 977 29
The endothelium is one of the largest cellular compartments of the human body and has a high proliferative potential. However, angiosarcomas are among the rarest malignancies. Despite this interesting contradiction, data on growth and angiogenesis control mechanisms of angiosarcomas are scarce. In this study of 19 angiosarcomas and 10 benign vascular control lesions we investigated the sequence and expression of the
p53 tumor suppressor
gene and the expression of the mdm-2 proto-oncogene, which is a negative regulator of
p53
activity and of the
vascular endothelial growth factor
(
VEGF
), whose expression, among other factors, is regulated by the
p53
/MDM-2 pathway. Ten sarcomas (53%) exhibited clear nuclear
p53 protein
accumulation. Two of these cases revealed mutations in the sequence-specific DNA binding domain of the
p53
gene. Thirteen angiosarcomas (68%) showed an increased amount of MDM-2 protein. Elevated expression of
p53
and MDM-2 protein correlated with increased
VEGF
expression, which was found in nearly 80% of the angiosarcoma cases. Negative or clearly lower immunostaining was obtained in cases from the benign control collective. Only one case of a juvenile hemangioma reached the cutoff value of
p53
positivity coincidentally with high
VEGF
expression. Our data suggest that the
p53
/ MDM-2 pathway is impaired in about two-thirds (14/ 19) of the angiosarcomas. This may be a key event in the pathogenesis of human angiosarcomas. The increased
VEGF
expression observed supports this hypothesis.
...
PMID:MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. 981 33
Local gene transfer into the vascular wall offers a promising alternative to treat atherosclerosis-related diseases at cellular and molecular levels. Blood vessels are among the easiest targets for gene therapy because of novel percutaneous, catheter-based treatment methods. On the other hand, gene transfer to the artery wall can also be accomplished from adventitia, and in some situations intramuscular gene delivery is also a possibility. In most conditions, such as postangioplasty restenosis, only a temporary expression of the transfected gene will be required. Promising therapeutic effects have been obtained in animal models of restenosis with the transfer of genes for
vascular endothelial growth factor
, fibroblast growth factor, thymidine kinase,
p53
, bcl-x, nitric oxide synthase and retinoblastoma. Also, growth arrest homeobox gene and antisense oligonucleotides against transcription factors or cell cycle regulatory proteins have produced beneficial therapeutic effects. Angiogenesis is an emerging new target for gene therapy of ischemic diseases. In addition, hyperlipoproteinemias may be improved by transferring functional lipoprotein-receptor genes into hepatocytes of affected individuals. First experiences of gene transfer methods in the human vascular system have been reported. However, further studies regarding gene delivery methods, vectors and safety of the procedures are needed before a full therapeutic potential of gene therapy in vascular diseases can be evaluated.
...
PMID:Vascular gene transfer for the treatment of restenosis and atherosclerosis. 981 1
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>